ABSTRACT
BACKGROUND: The SARS-CoV-2 virus has impacted life in many ways, one change being the use of face masks. Their effect on MRI-based measurements of cerebral oxygen levels with quantitative susceptibility mapping (QSM) and cerebral blood flow (CBF) is not known. PURPOSE: This study investigated whether wearing a face mask leads to changes in CBF and cerebral venous oxygen saturation measured with MRI. STUDY TYPE: Repeated-measures cohort study. POPULATION: A total of 16 healthy volunteers (eight male, eight female; 22-36 years) were recruited for the 3-ply study. Ten of the 16 participants (five male, five female; 23-36 years) took part in the KN95 study. FIELD STRENGTH/SEQUENCE: A 3 T, single-delay 3D gradient-and spin-echo pseudo-continuous arterial spin labeling (pCASL) scan for CBF quantification, and gradient-echo for QSM and oxygenation quantification. ASSESSMENT: Gray matter CBF and magnetic susceptibility were assessed by masking the pCASL CBF map and the QSM map to the T1 -weighted gray matter tissue segmentation. Venous oxygenation was determined from venous segmentation of QSM maximum intensity projections. STATISTICAL TESTS: Paired Student's t-tests and Cohen's d effect sizes were used to compare the face mask and no face mask scans for gray matter CBF, gray matter magnetic susceptibility, and cerebral venous oxygen saturation. Standard t-tests were used to assess whether the order of scanning with and without a mask had any impact. A statistical cut off of P < 0.05 was used. RESULTS: The 3-ply masks increased gray matter CBF from an average of 43.99 mL/(100 g*min) to 46.81 mL/(100 g*min). There were no significant changes in gray matter magnetic susceptibility (P = 0.07), or cerebral venous oxygen saturation (P = 0.36) for the 3-ply data set. The KN95 masks data set showed no statistically significant changes in gray matter CBF (P = 0.52) and magnetic susceptibility (P = 0.97), or cerebral venous oxygen saturation (P = 0.93). DATA CONCLUSION: The changes in blood flow and oxygenation due to face masks are small. Only CBF increased significantly due to wearing a 3-ply mask. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 3.
ABSTRACT
The global pandemic caused by SARS-CoV-2, or COVID-19, continues to impact all facets of daily life. Clinical manifestations of COVID-19 commonly include musculoskeletal symptoms such as myalgias, arthralgias, and neuropathies/myopathies. The inflammatory response and its impact on the respiratory system have been the focus of most studies. However, the literature is more limited regarding the inflammatory response and its implications for other organ systems, specifically the musculoskeletal system. Previous studies have described how systemic inflammation may play a role in bone and joint pathology. Furthermore, it is important to understand the effects current therapeutics used in the treatment of COVID-19 may have on the musculoskeletal system. In this study, we will review the current understanding of the effect COVID-19 has on the musculoskeletal system, provide an overview of musculoskeletal symptoms of patients infected with the virus, and address key issues for clinicians to address during the care of COVID-19 patients.